← All Heron Therapeutics, INC /DE/ filings

Heron Therapeutics, INC /DE/ 8-K filings

NASDAQ
HRTX
Heron Therapeutics, INC /DE/
8-K: Heron Therapeutics Submits FDA Application for ZYNRELEF Vial Access Needle, Aiming to Streamline Post-Surgical Pain Management
Heron Therapeutics has submitted a Prior Approval Supplement to the FDA for a new Vial Access Needle for ZYNRELEF, designed to reduce preparation time and improve ease of use.
NASDAQ
HRTX
Heron Therapeutics, INC /DE/
8-K: Heron Therapeutics Reports Improved First Quarter 2024 Results Driven by Revenue Growth and Margin Expansion
Heron Therapeutics announced positive first quarter 2024 results, highlighted by increased product sales, improved gross margins, and a reduced net loss per share.
NASDAQ
HRTX
Heron Therapeutics, INC /DE/
8-K: Heron Therapeutics Appoints Ira Duarte as Principal Accounting Officer, Replacing Lisa Peraza
Heron Therapeutics has announced the appointment of Ira Duarte as its new principal accounting officer, effective March 29, 2024, replacing Lisa Peraza.
NASDAQ
HRTX
Heron Therapeutics, INC /DE/
8-K: Heron Therapeutics Reports Strong 2023 Oncology Sales, Reaffirms 2024 Guidance
Heron Therapeutics announced its fourth quarter and full-year 2023 financial results, highlighting strong oncology sales and reaffirming its 2024 financial guidance.
NASDAQ
HRTX
Heron Therapeutics, INC /DE/
8-K: Heron Therapeutics' ZYNRELEF Receives FDA Approval for Expanded Use in Orthopedic and Soft Tissue Procedures
The FDA has approved an expanded indication for Heron Therapeutics' ZYNRELEF, now covering an estimated 13 million procedures annually, marking an 86% increase over prior indications.
NASDAQ
HRTX
Heron Therapeutics, INC /DE/
8-K: Heron Therapeutics Partners with CrossLink to Expand ZYNRELEF Sales Network
Heron Therapeutics has partnered with CrossLink Life Sciences to significantly expand the sales and promotion of their non-opioid pain relief product, ZYNRELEF, in the United States.